Fluorodesoxyglucose uptake in the remaining adrenal glands during the follow-up of patients with adrenocortical carcinoma: Do not consider it as malignancy

European Journal of Endocrinology

Volumn 164, Issue 1, 2011, Pages 89-94

  Leboulleux, S ^a   Deandreis, D ^a   Escourrou, C ^a   Al Ghuzlan, A ^a   Bidault, F ^a   Auperin A ^a   Travagli, J P ^a   Lumbroso, J ^a   Schlumberger, M ^a   Baudin, E ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MITOTANE;

ADRENAL CORTEX CARCINOMA; ADRENAL GLAND; ADRENALECTOMY; ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; AGED; CONTRAST ENHANCEMENT; DIFFERENTIAL DIAGNOSIS; DRUG TISSUE LEVEL; DRUG UPTAKE; IMAGE ANALYSIS; MALIGNANT NEOPLASTIC DISEASE; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADRENAL CORTEX NEOPLASMS; ADRENAL GLANDS; ADRENALECTOMY; ADRENOCORTICAL CARCINOMA; ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PHEOCHROMOCYTOMA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 78751522566     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0666     Document Type: Article

References (28)

1. Tessonnier L, Sebag F, Palazzo FF, Colavolpe C, De Micco C, Mancini J, Conte-Devolx B, Henry JF, Mundler O & Taieb D. Does (18)F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours? European Journal of Nuclear Medicine and Molecular Imaging 2008 35 2018-2025. (doi:10.1007/s00259-008-0849-3)
2. Groussin L, Bonardel G, Silvera S, Tissier F, Coste J, Abiven G, Libe R, Bienvenu M, Alberini JL, Salenave S, Bouchard P, Bertherat J, Dousset B, Legmann P, Richard B, Foehrenbach H, Bertagna X & Tenenbaum F. 18F- Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. Journal of Clinical Endocrinology and Metabolism 2009 94 1713-1722. (doi:10.1210/jc.2008- 2302)
3. Leboulleux S, Dromain C, Bonniaud G, Auperin A, Caillou B, Lumbroso J, Sigal R, Baudin E & Schlumberger M. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. Journal of Clinical Endocrinology and Metabolism 2006 91 920-925. (doi:10.1210/jc.2005-1540) (Pubitemid 43357759)
4. Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, Adams KT, Solis D, Lenders JW & Pacak K. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. Journal of Clinical Oncology 2007 25 2262-2269. (doi:10.1200/JCO.2006.09.6297)
5. Bagheri B, Maurer AH, Cone L, Doss M & Adler L. Characterization of the normal adrenal gland with 18F-FDG PET/CT. Journal of Nuclear Medicine 2004 45 1340-1343.
6. Meier JM, Alavi A, Iruvuri S, Alzeair S, Parker R, Houseni M, Hernandez-Pampaloni M, Mong A & Torigian DA. Assessment of age-related changes in abdominal organ structure and function with computed tomography and positron emission tomography. Seminars in Nuclear Medicine 2007 37 154-172. (doi:10.1053/j.semnuclmed.2007.02.001) (Pubitemid 46517469)
7. Weiss LM, Medeiros LJ & Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. American Journal of Surgical Pathology 1989 13 202-206. (doi:10.1097/00000478-198903000-00004)
8. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S & Allolio B. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009 115 243-250. (doi:10.1002/cncr.24030)
9. Assie G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, Leboulleux S, Travagli JP, Dromain C, Bertagna X, Bertherat J, Schlumberger M & Baudin E. Prognostic parameters of metastatic adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2007 92 148-154. (doi:10.1210/jc.2006- 0706)
10. Nowak M, Kasprzak A, Lesniewska B & Malendowicz LK. Studies on the compensatory growth of the adrenal cortex of the male hamster after unilateral adrenalectomy. Experimental Clinical Endocrinology 1989 94 269-274. (doi:10.1055/s-0029-1210909) (Pubitemid 20072268)
11. Nakayama T, Imai S, Soma M, Izumi Y & Kanmatsuse K. Compensatory adrenal growth and steroidogenesis after unilateral adrenalectomy. Endocrine Journal 1993 40 523-527. (doi:10.1507/endocrj.40.523)
12. Vincent JM, Morrison ID, Armstrong P & Reznek RH. The size of normal adrenal glands on computed tomography. Clinical Radiology 1994 49 453-455. (doi:10.1016/S0009-9260(05)81739-8)
13. Gross MD, Shapiro B, Freitas JE, Meyers L, Francis I, Thompson NW & Wortsman J. Clinical significance of the solitary functioning adrenal gland. Journal of Nuclear Medicine 1991 32 1882-1887.
14. Reddy MP & Ramaswamy MR. FDG uptake in brown adipose tissue mimicking an adrenal metastasis: source of false-positive interpretation. Clinical Nuclear Medicine 2005 30 257-258. (doi:10.1097/01.rlu.0000156798.59230.2e)
15. 18FDG uptake in brown fat: potential for false positives. Radiologic Technology 2007 78 361-366.
16. Pommier RF & Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992 112 963-970 (discussion 970-971).
17. Evans HL & Vassilopoulou-Sellin R. Adrenal cortical neoplasms. A study of 56 cases. American Journal of Clinical Pathology 1996 105 76-86. (Pubitemid 26024771)
18. Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, Dousset B, Bertagna X & Bertherat J. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. Journal of Clinical Endocrinology and Metabolism 2006 91 2650-2655. (doi:10.1210/jc.2005-2730)
19. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L & Berruti A. Adjuvant mitotane treatment for adrenocortical carcinoma. New England Journal of Medicine 2007 356 2372-2380. (doi:10.1056/NEJMoa063360)
20. Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E & Sturgeon C. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 2008 113 3130-3136. (doi:10.1002/cncr.23886)
21. Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G & Schlumberger M. Impact of monitoring plasma 1,1- dichlorodiphenildichloroethane (o,p′-DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001 92 1385-1392. (doi:10.1002/1097-0142(20010915)92:6〈1385::AID-CNCR1461〉3.0.CO;2-2)
22. Donadille B, Groussin L, Waintrop C, Abbas H, Tenenbaum F, Dugue MA, Coste J, Bertagna X & Bertherat J. Management of Cushing's syndrome due to ectopic adrenocorticotropin secretion with 1,ortho-1, para′-dichloro- diphenyl-dichloro-ethane: findings in 23 patients from a single center. Journal of Clinical Endocrinology and Metabolism 2010 95 537-544. (doi:10.1210/jc.2009- 1317)
23. Alexandraki KI, Kaltsas GA, le Roux CW, Fassnacht M, Ajodha S, Christ-Crain M, Akker SA, Drake WM, Edwards R, Allolio B & Grossman AB. Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. Clinical Endocrinology 2010 72 305-311. (doi:10.1111/j.1365-2265.2009.03631.x)
24. Orth DN & Kovacs WJ. The adrenal cortex. In Williams Textbook of Endocrinology, 9th edn, pp 517-664. Eds JD Wilson, DW Foster, HM Kronenberg & PR Larsen. Philadelphia: W.B. Saunders Company, 1998.
25. 18F-FDG PET/CT in identification of ectopic ACTH secretion tumors. Endocrine 2009 36 385-391. (doi:10.1007/s12020-009-9247-2)
26. Markou A, Manning P, Kaya B, Datta SN, Bomanji JB & Conway GS. [18F]fluoro-2-deoxy-D-glucose ([18F]FDG) positron emission tomography imaging of thymic carcinoid tumor presenting with recurrent Cushing's syndrome. European Journal of Endocrinology 2005 152 521-525. (doi:10.1530/eje.1.01839)
27. Favier J, Briere JJ, Burnichon N, Riviere J, Vescovo L, Benit P, Giscos-Douriez I, De Reynies A, Bertherat J, Badoual C, Tissier F, Amar L, Libe R, Plouin PF, Jeunemaitre X, Rustin P & Gimenez-Roqueplo AP. The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS ONE 2009 4 e7094. (doi:10.1371/journal.pone.0007094)
28. Martz F & Straw JA. Metabolism and covalent binding of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p′-DDD). Correlation between adrenocorticolytic activity and metabolic activation by adrenocortical mitochondria. Drug Metabolism and Disposition 1980 8 127-130.